Seroatlas · Human Serome Atlas

ARFGAP2

ADP-ribosylation factor GTPase-activating protein 2

Also known as: ARFG2_HUMAN, FLJ14576, IRZ, Zfp289, ZNF289

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N6H7
Gene: ARFGAP2
Ensembl: ENSG00000149182
Chromosome: 11
Canonical length: 521 aa
Protein class: Predicted intracellular proteins
Subcellular location: Golgi apparatus

OverviewNCBI Gene

Predicted to enable GTPase activator activity. Predicted to be involved in COPI coating of Golgi vesicle. Located in Golgi apparatus; cytosol; and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

521 residues, UniProt reviewed canonical sequence.

>Q8N6H7|ARFGAP2
     1  MAAEPNKTEI QTLFKRLRAV PTNKACFDCG AKNPSWASIT YGVFLCIDCS GVHRSLGVHL
    61  SFIRSTELDS NWNWFQLRCM QVGGNANATA FFRQHGCTAN DANTKYNSRA AQMYREKIRQ
   121  LGSAALARHG TDLWIDNMSS AVPNHSPEKK DSDFFTEHTQ PPAWDAPATE PSGTQQPAPS
   181  TESSGLAQPE HGPNTDLLGT SPKASLELKS SIIGKKKPAA AKKGLGAKKG LGAQKVSSQS
   241  FSEIERQAQV AEKLREQQAA DAKKQAEESM VASMRLAYQE LQIDRKKEEK KLQNLEGKKR
   301  EQAERLGMGL VSRSSVSHSV LSEMQVIEQE TPVSAKSSRS QLDLFDDVGT FASGPPKYKD
   361  NPFSLGESFG SRWDTDAAWG MDRVEEKEPE VTISSIRPIS ERATNRREVE SRSSGLESSE
   421  ARQKFAGAKA ISSDMFFGRE VDAEYEARSR LQQLSGSSAI SSSDLFGDMD GAHGAGSVSL
   481  GNVLPTADIA QFKQGVKSVA GKMAVLANGV MNSLQDRYGS Y

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ARFGAP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Other membrane
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.56
Highest tissue expression: 112 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 112 nTPM
liver: 75 nTPM
bone marrow: 73 nTPM
skin: 72 nTPM
cerebellum: 69 nTPM
tongue: 67 nTPM

Single-cell type

syncytiotrophoblasts: 116 nCPM
thymic myoid cells: 78 nCPM
cytotrophoblasts: 77 nCPM
megakaryocytes: 68 nCPM
migrating cytotrophoblasts: 63 nCPM
esophageal apical cells: 61 nCPM

Immune cell

basophil: 107 nTPM
total PBMC: 104 nTPM
non-classical monocyte: 97 nTPM
eosinophil: 89 nTPM
intermediate monocyte: 76 nTPM
gdT-cell: 70 nTPM

Brain region

white matter: 68 nTPM
medulla oblongata: 63 nTPM
thalamus: 58 nTPM
basal ganglia: 58 nTPM
cerebral cortex: 58 nTPM
cerebellum: 57 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.54
gnomAD pLI: 0
gnomAD missense Z: 0.7
DepMap mean gene effect: 0
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ARFGAP2 as an antibody target. Whether an autoantibody or antibody against ARFGAP2 could matter depends on whether native ARFGAP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ARFGAP2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ARFGAP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...